Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The UK Government has authorised the use of anti-inflammatory drug dexamethasone for the treatment of Covid-19 on the National Health Service (NHS), immediately after the report of positive data from the RECOVERY trial.
Preliminary data showed that the low-cost, commonly available drug reduced death by up to one third in hospitalised patients with severe respiratory complications caused by Covid-19.
The drug has been approved for the treatment of patients needing oxygen, including those on ventilators. According to the trial results, dexamethasone decreased the risk of death by 35% in patients on ventilation and 20% in patients.
Read more on pharmaceutical-technology.com